D. Coakley

发表

Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults

J. Kahn, P. Barditch-Crovo, A. Collier, 2001, Antimicrobial Agents and Chemotherapy.

Single-Dose and Steady-State Pharmacokinetics of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Children

S. Steinberg, F. Balis, S. Zeichner, 2004, Antimicrobial Agents and Chemotherapy.

Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes.

Brendan H. Lee, G. Diaz, B. Scharschmidt, 2014, Molecular genetics and metabolism.

Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy

D. Rockey, J. Bajaj, B. Scharschmidt, 2016, Digestive Diseases and Sciences.

Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis.

D. Rockey, B. Scharschmidt, M. Ghabril, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate.

Brendan H. Lee, G. Diaz, B. Scharschmidt, 2013, The Journal of pediatrics.

Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy

D. Rockey, K. Reddy, K. G. Reddy, 2014, Hepatology.

Urinary phenylacetylglutamine (U-PAGN) concentration as biomarker for adherence in patients with urea cycle disorders (UCD) treated with glycerol phenylbutyrate

Brendan H. Lee, G. Diaz, B. Scharschmidt, 2015, Molecular genetics and metabolism reports.

Population Pharmacokinetic Modeling and Dosing Simulations of Nitrogen‐Scavenging Compounds: Disposition of Glycerol Phenylbutyrate and Sodium Phenylbutyrate in Adult and Pediatric Patients with Urea Cycle Disorders

G. Diaz, B. Scharschmidt, U. Lichter-Konecki, 2013, Journal of clinical pharmacology.

Patterns of Resistance Emerging in HIV-1 From Antiretroviral-Experienced Patients Undergoing Intensification Therapy With Tenofovir Disoproxil Fumarate

M. Wulfsohn, A. Cheng, N. Margot, 2004, Journal of acquired immune deficiency syndromes.

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Joel E Gallant, Edwin DeJesus, Schlomo Staszewski, 2004, JAMA.

Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate

S. Cederbaum, N. Longo, Brendan H. Lee, 2013, Hepatology.

Disposition of didanosine in HIV‐seropositive patients with normal renal function or chronic renal failure: Influence of hemodialysis and continuous ambulatory peritoneal dialysis

G. Dukes, S. Kaul, R. Falk, 1996, Clinical pharmacology and therapeutics.

Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease

M. Jacobson, S. Weller, J. Gallant, 1994, Antimicrobial Agents and Chemotherapy.

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.

M. Wulfsohn, J. Kahn, S. Lagakos, 1999, JAMA.

A Randomized, Double-Blind Trial of Valaciclovir Prophylaxis for Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Infection

D. Cooper, M. Youle, P. Griffiths, 1998 .

A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.

M. Youle, P. Griffiths, M. Gill, 1998, The Journal of infectious diseases.

Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection

M. Wulfsohn, K. Squires, A. Pozniak, 2003, Annals of Internal Medicine.

Background: Resistance to antiretroviral agents remains a lead- ing cause of treatment failure for patients infected with HIV-1.

M. Wulfsohn, K. Squires, A. Pozniak, 2003 .

Single-Dose Pharmacokinetics and Safety of the Oral Antiviral Compound Adefovir Dipivoxil in Children Infected with Human Immunodeficiency Virus Type 1

S. Blanchard, J. Rodman, J. Shenep, 2000, Antimicrobial Agents and Chemotherapy.

Efficacy and Safety of Adefovir Dipivoxil With Antiretroviral Therapy

Michael I. Miller, M. Wulfsohn, J. Kahn, 2017 .

Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.

William A. Lee, M. Wulfsohn, A. Zolopa, 2014, The Journal of antimicrobial chemotherapy.

Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.

D. Rockey, N. Longo, G. Diaz, 2013, Molecular genetics and metabolism.

Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.

J L Merritt, B F Scharschmidt, S. Cederbaum, 2012, Molecular genetics and metabolism.

Glutamine and hyperammonemic crises in patients with urea cycle disorders.

M. Marino, N. Longo, Brendan H. Lee, 2016, Molecular genetics and metabolism.

Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals

Christine Hogan, Alan S Perelson, A. Perelson, 2003, AIDS.

Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients

J. Gallant, S. Staszewski, A. Pozniak, 2004 .

Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary

M. Margolis, J. Bajaj, B. Scharschmidt, 2016, Metabolic Brain Disease.

Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate.

A. Collier, S. Deeks, I. McGowan, 2001, Journal of acquired immune deficiency syndromes.

BLOOD AMMONIA AND GLUTAMINE AS PREDICTORS OF HYPERAMMONEMIC CRISES IN UREA CYCLE DISORDER PATIENTS

M. Marino, S. Cederbaum, J. Vockley, 2014, Genetics in Medicine.

Effect of Tenofovir Disoproxil Fumarate on the Pharmacokinetics and Pharmacodynamics of Total, R‐, and S‐Methadone

B. Kearney, Patrick F. Smith, J. Flaherty, 2004, Pharmacotherapy.

Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary

K. Coyne, M. Margolis, J. Bajaj, 2016, Metabolic brain disease.

Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.

D. Rockey, N. Longo, Brendan H. Lee, 2013, Molecular genetics and metabolism.

Glycerol Phenylbutyrate in Patients With Cirrhosis and Episodic Hepatic Encephalopathy: A Pilot Study of Safety and Effect on Venous Ammonia Concentration

D. Rockey, B. Scharschmidt, M. Ghabril, 2013, Clinical pharmacology in drug development.

Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate

S. Cederbaum, N. Longo, Brendan H. Lee, 2013, Hepatology.

Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.

M. Marino, S. Cederbaum, J. Vockley, 2015, Molecular genetics and metabolism.

Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes.

Brendan H. Lee, G. Diaz, B. Scharschmidt, 2014, Molecular genetics and metabolism.

BLOOD AMMONIA AND GLUTAMINE AS PREDICTORS OF HYPERAMMONEMIC CRISES IN UREA CYCLE DISORDER PATIENTS

S. Cederbaum, J. Vockley, N. Longo, 2014, Genetics in Medicine.